Fractyl Health Inc GUTS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 11, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-96,517

Price:

$2.47
Nov 11, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-64,197

Price:

$2.47
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-216,924

Price:

--
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

216,924

Price:

--
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-187,257

Price:

--
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

187,257

Price:

--
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-95,484

Price:

--
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-65,000

Price:

$2.90
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

95,484

Price:

$1.70
May 14, 2024 (filed on May 14, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3/A : Amendment of a previous Form 3

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-216,924

Price:

--
Nov 11, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-96,517

Price:

$2.47
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

216,924

Price:

--
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-187,257

Price:

--
Nov 11, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-64,197

Price:

$2.47
Nov 10, 2024 (filed on Nov 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

187,257

Price:

--
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-95,484

Price:

--
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-65,000

Price:

$2.90
Sep 12, 2024 (filed on Sep 13, 2024)

Insider Name:

Caplan Jay David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

95,484

Price:

$1.70
May 14, 2024 (filed on May 14, 2024)

Insider Name:

Rajagopalan Harith

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3/A : Amendment of a previous Form 3

# or value acquired/disposed of:

--

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	3 Van De Graaff Drive, Suite 200 BURLINGTON MA 01803
Tel:	1-781-9028800
Website:	https://www.fractyl.com
IR:	See website

Key People

Jay D. Caplan President, Co-Founder, Chief Product Officer	Harith Rajagopalan Chief Executive Officer, Co-Founder, Director	Lisa A. Davidson Chief Financial Officer, Treasurer
Timothy Kieffer Chief Scientific Officer	Sarah Toomey General Counsel, Corporate Secretary	Adrian Kimber Chief Commercial Officer

Business Overview

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company's lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Financial Overview

For the nine months ended 30 September 2024, Fractyl Health Inc revenues decreased 20% to $90K. Net loss applicable to common stockholders decreased 36% to $45.5M. Revenues reflect Biotechnology & Medical Research segment decrease of 61% to $14K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.49 to -$0.95.

Employees:	102 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$34.64M as of Sep 30, 2024
Annual revenue (TTM):	$0.10M as of Sep 30, 2024
EBITDA (TTM):	-$80.81M as of Sep 30, 2024
Net annual income (TTM):	-$68.97M as of Sep 30, 2024
Free cash flow (TTM):	-$60.75M as of Sep 30, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	48,098,944 as of Nov 1, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization